Why the study?
What proportion of patients hospitalized with HFrEF are eligible for sacubitril/valsartan based on FDA labeling versus PARADIGM-HF trial criteria?
What proportion of patients hospitalized with HFrEF are eligible for sacubitril/valsartan based on FDA labeling versus PARADIGM-HF trial criteria?
A large majority (69%) of patients hospitalized with HFrEF meet FDA labeling criteria for sacubitril/valsartan, highlighting a broad scope for potential implementation in real-world practice compared to stricter trial criteria.
No takes yet. Share an insight, caveat, or question.
Highlights a broad scope for real-world implementation beyond strict trial criteria; leaves open whether this expanded eligibility.
Parikh et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: